HS-10515 / Jiangsu Hansoh Pharma - LARVOL DELTA

Preclinical assessment of WRN inhibitor HS-10515 for selective targeting of MSI-H cancers (AACR-NCI-EORTC 2025) - "HS-10515 demonstrated robust inhibition of WRN activity and induced strong anti-proliferative effects in a panel of MSI-H cancer cell lines derived from colorectal, endometrial, and gastric tumors. Both compounds exhibit favorable drug-like properties, including excellent pharmacokinetic (PK) profiles, significant tumor growth inhibition, with pharmacodynamic (PD) biomarker induction and WRN degradation closely correlating with efficacy, supporting their advancement into clinical development."

IO biomarker • MSI-H • Preclinical • Gastric Cancer • Microsatellite Instability • Oncology • MSI • WRN